Abstract: The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

Abstract: Methods of treating skin neoplasms using a monoamine oxidase inhibitor, e.g., a propynylaminoindan (such as rasagiline) are provided. Pharmaceutical compositions and kits comprising monoamine oxidase inhibitors are also provided.

Abstract: Homogeneous stable liquid agrochemical concentrate formulations which form stable dilutions with water comprises biologically efficacious oil, water, agrochemical dissolved in the water to form concentrated aqueous electrolyte, a stabilizing surfactant, based on non-ionic or non-ionic and anionic or amphoteric surfactant, comprising oil compatible, electrolyte tolerant surfactant and water soluble, electrolyte tolerant surfactant and optionally a polyol component, are useful as tank mix adjuvants. The formulations combine biologically efficacious oil, e.g. crop oil, with an electrolyte agrochemical, particularly water soluble non-selective herbicide such as glyphosate, or electrolyte nutrients particularly water soluble inorganic fertilizers providing nutrients such as nitrogen, phosphorus, potassium or sulphur.

Abstract: Sudden cardiac arrest is treated by reducing blood temperature from about 37° C. to 33° C., following resuscitation, by injecting hypothermia inducing drugs such as a cannabinoid type into the patient's body, preferably in combination with physical surface body cooling.

Abstract: The present invention relates to small molecule protein tyrosine phosphatase inhibitors, especially Shp-2 inhibitors, of formula (I) and/or (II), and to pharmaceutical compositions comprising them. The invention is also directed to the use of said compounds for the treatment of phosphatase-mediated diseases, especially cancer and metastasis. The invention further concerns a method for treating a proliferative disease, a genetic disorder, an autoimmune disease, an angiogenic disorder or cancer in a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of at least one compound of formula (I) and/or (II).

Abstract: A compound represented by the following general formula (IA) or a salt thereof: wherein Ar1 represents hydrogen atom or an aryl group having at least one iodine atom as a substituent; Ar2 represents an aryl group having at least one iodine atom as a substituent; L1 and L2 independently represent a divalent bridging group of which main chain contains 6 or more carbon atoms; L3 represents a single bond or a divalent bridging group of which main chain contains 1 to 6 carbon atoms and one oxygen atom; X represents a functional group containing at least one heteroatom, provided that, when L3 is a single bond, X represents a functional group other than hydroxyl group. The compound can be used as a membrane component of liposomes, and the liposomes can be used as a contrast medium for X-ray radiography.

Abstract: An aqueous disinfecting solution and dry powdered composition which may be dissolved in water to provide the solution. The solution has a pH of from 0.6 to 7 and comprises (a) hydrogen peroxide in a concentration of from 0.01 to 6% w/w; and (b) at least one component chosen from cyclic carboxylic acids and aromatic alcohols, in a concentration of from 0.01 to 4 w/w %, all based on the total weight of the solution. The cyclic carboxylic acids are preferably 2-furan carboxylic acid, benzoic acid and salicylic acid. Furthermore, the solution preferably contains at least one C6-C12 alkyl diphenyl oxide sulfonate surfactant and a nonionic surfactant. Additional optional ingredients include anionic surfactants, corrosion inhibitors, cation sequestering agents, and buffers.

Abstract: A self-reversible reverse microlatex composition comprising an oil phase, an aqueous phase, at least one W/O surfactant, at least one O/W surfactant, and a branched or a crosslinked polyelectrolyte, wherein the W/O surfactant and the O/W surfactant mixture have a HLB from about 9.5 to about 10, and the polyelectrolyte is either a homopolymer or copolymer or a combination thereof based on at least one monomer containing a strong or weak acid function. Further, the composition may be used in the cosmetic, dermopharmaceutical, pharmaceutical, textile, paper, and/or paint industries, or as a thickener for printing pastes based on pigments or dyes.

Abstract: Novel ultrasound methods comprising administering to a patient a targeted vesicle composition which comprises vesicles comprising a lipid, protein or polymer, encapsulating a gas, in combination with a targeting ligand, and scanning the patient using ultrasound. The scanning may comprise exposing the patient to a first type of ultrasound energy and then interrogating the patient using a second type of ultrasound energy. The targeting ligand preferably targets tissues, cells or receptors, including myocardial cells, endothelial cells, epithelial cells, tumor cells and the glycoprotein GPIIbIIIa receptor. The methods may be used to detect a thrombus, enhancement of an old or echogenic thrombus, low concentrations of vesicles and vesicles targeted to tissues, cells or receptors.

Abstract: Compounds, preparations and methods for immunosuppressive treatment of autoimmune disorders, graft rejection and/or graft/host disease. Therapeutically effective amounts of certain substituted triarylmethane compounds, such as 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole, are administered to mammalian patients to selectively inhibit the calcium-activated K+ channel (IKCa1) in lymphocytes, monocytes, macrophages, platelets or endothelial cells without concomitant inhibition of P450-dependent enzyme systems, resulting in reduction of antigen-, cytokine-, or mitogen-induced calcium entry through store operated calcium channels in these cells, suppression of cytokine production by these cells, and inhibition of activation of these cells. Such inhibition of the Ca++ activated K+ channel (IKCa1) prevents the pre-Ca++ stage of cell activation and thus causes immunosuppression and an anti-inflammatory response.

Abstract: Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

Abstract: A personal care or cosmetic product composition that includes from about 0.1% to about 99% of at least one ester of alkoxylated aromatic alcohol and fatty carboxylic acid, and from about 0.1% to 60% of at least one functional ingredient is provided. The functional ingredients in the composition may include active ingredients and additional ingredients. Especially suitable active ingredients are sunscreen active ingredients and antiperspirant active ingredients. Preferred compositions are sunscreen product formulations and antiperspirant products. In one preferred embodiment, the composition further includes at least one cyclomethicone compound present in the amount of from about 1% to 99% by weight of the composition. A method of improving the protection of human or animal skin or hair from radiation and a method of improving the protection of human or animal skin or hair from perspiration are also provided.

Abstract: A composition and method are provided for alleviating the dermatological signs of intrinsic and extrinsic aging. A topical formulation containing a cosmeceutically active base, wherein the formulation provides a pH in the range of about 8.0 to 13.0 at the skin surface, is applied to the skin in order to prevent or treat aging-related skin conditions such as wrinkles, dry skin, age spots, sun damage (particularly UV radiation-induced oxidative stress), blemishes, hyperpigmented skin, age spots, increased skin thickness, loss of skin elasticity and collagen content, dry skin, lentigines and melasmas. The cosmeceutically active base is either an inorganic base, such as an inorganic hydroxide, an inorganic oxide, or a metal salt of a weak acid, or an organic base, particularly a nitrogenous base such as may be selected from primary amines, secondary amines, tertiary amines, amides, oximes, nitrites, aromatic and non-aromatic nitrogen-containing heterocycles, urea, and mixtures thereof.

Abstract: Therapeutic methods of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (1), in which Z is H, R1 is H, or RACO where RA is C1-10alkyl or an amino acid, R2 is H, OH, or ORB where RB is an amino acid, or CORA where RA is as previously defined, W is H, A is H or OH, and B is selected from (a), (b), (c), or W is H, and A and B taken together form a six-membered ring selected from (d), or W, A and B taken with the groups with which they are associated comprise (e), or W and A taken together with the groups with which they are associated comprise (f) and B is (g) wherein R3 is H, CORA where RA is as previously defined, CO2Rc where RC is C1-10alkyl, or CORB where RB is as previously defined, R4 is H, CORD where RD is H, OH, C1-10alkyl or an amino acid, CO2RC where RC is as previously defined, CORE where RE is H, C1-10alkyl or an amino acid, COOH, CORC where RC is as previously defined, or CONHRE where RE is as previously defined, R5 is H, CORC where

Abstract: A coated preparation for the detection of a H. pylori infection according to a urea breath test protocol which comprises a core composition containing at least an isotope C-labeled urea, an excipient and a lubricant in defined proportions and covered with 0.1˜10 weight % of a coating agent based on 100 weight % of the core composition. With this preparation, the influence of the urease-producing bacteria resident in organs other than the stomach, such as the mouth and throat, is excluded to enable a diagnosis of H. pylori infection without the risk for a false-positive test and with reasonable rapidity.

Abstract: Modulating the metabolism of a dieting mammal by administering to the dieting mammal the metabolic modulating agent 7-oxo DHEA or a pro-drug thereof incapable of in vivo conversion to testosterone.

Abstract: A topical skin composition containing a dipeptide compound represented by formula (1) or a salt of the dipeptide: wherein R1 represents a hydrogen atom, an alkyl group, an alkanoyl group, or —CH(R6)COOR7 (wherein R6 represents a hydrogen atom or a lower alkyl group, and R7 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, or an aralkyl group); R2 represents a hydrogen atom or an alkyl group which may have a substituent; R3 represents a lower alkyl group or a phenyl group; R4 represents a hydrogen atom or a lower alkyl group, and may form a heterocyclic ring together with R5 and an adjacent nitrogen atom; R5 represents a hydrogen atom, an alkyl group which may have a substituent, or an aralkyl group which may have a substituent, and may form the heterocyclic ring together with R4; X represents —COOR8 (wherein R8 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, or an aralkyl group) or —SO3H; and n is an integer of 0-4; and a pharmaceutically acceptable carrier

Abstract: The invention relates to the use of flumazenil to produce a medicament for the treatment of cocaine dependency. The flumazenil can be administered sequentially in small quantities at short intervals until a therapeutically effective quantity for the treatment of cocaine dependency has been administered.

Abstract: A method and composition for the treatment of hormone allergy is disclosed. The method relates to using progesterone dilutions, or any other steroid hormone, to treat the systemic symptoms of hormone allergy, including pain. The composition of the hormone dilutions ranges from 10?1 to 10?5. The hormone dilution may be administered sublingually, or, in the alternative, an intradermal route of administration may be chosen. Hormone dilutions may be administered at daily intervals or on any other treatment schedule as required to alleviate a patient's symptoms.

Abstract: The present invention relates to a composition for topical use for treating and improving the aesthetic conditions of the skin, which comprises, as an active ingredient, a mixture of ethyllinoleate and triethylcitrate. This composition is active in the treatment of seborrhea and acne.